Navigation Links
Octapharma Accepting Applications for Research Grants on Immunotherapy, Coagulation Disorders and Critical Care
Date:7/23/2009

LACHEN, Switzerland and HOBOKEN, N.J., July 23 /PRNewswire/ -- Octapharma USA is now accepting applications for the Octapharma 25th Anniversary Grants Program, which supports clinical or pre-clinical research focused on human protein therapies in coagulation disorders, immunotherapy, intensive care and emergency medicine. Applications will be reviewed in October.

Octapharma AG, the third largest plasma products manufacturer in the world, launched the grants program in celebration of its 25(th) anniversary. The company's first ever grants program is only available to researchers based in the United States and is administered by Octapharma USA, the Swiss company's rapidly-growing U.S. subsidiary.

"We have been committed to patient care and medical innovation since day one and our vision of providing patients with the safest, highest quality human protein therapies available is stronger than ever," said Octapharma USA President Flemming Nielsen. "The Octapharma 25(th) Anniversary Grants Program is our latest initiative to help improve the lives of people around the world."

Grant applications are accepted online only at www.octapharmagrants.com. All grant requests will be evaluated by the Octapharma 25(th) Anniversary Grants Committee in October and the first grants recipients will be announced shortly afterward. Please visit www.octapharmagrants.com for a complete description of the grants program, including the application and review process.

Octapharma AG

Octapharma AG is the third largest plasma products manufacturer in the world and has been committed to patient care and medical innovation for over 25 years. Octapharma's core business is the development, production and sale of high quality human protein therapies, including immune globulin intravenous (IGIV). In the U.S., Octapharma's IGIV product, octagam(R) (immune globulin intravenous [human] 5%), is used to treat disorders of the immune system, and Octapharma's Albumin (Human) is indicated for the restoration and maintenance of circulating blood volume. Based in Lachen, Switzerland, Octapharma employs over 3,000 people and has biopharmaceutical experience in 80 countries worldwide, including the United States, where Octapharma USA is headquartered in Hoboken, N.J. Octapharma operates two state-of-the-art production sites licensed by the U.S. Food and Drug Administration, providing the highest level of production flexibility and minimizing product shortages. For more information, please visit www.octapharma.com or call Octapharma USA at 201-604-1130.


'/>"/>
SOURCE Octapharma USA
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Plasma Products Safe Despite Swine Influenza Outbreak, Assures International Biopharmaceutical Company Octapharma
2. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Files Three Patent Applications
3. Raptor Pharmaceuticals Receives Notices of Allowance for Two NeuroTrans(TM) Patent Applications
4. OmegaGenesis Unveils Novel Nanotechnology Platform With Broad Biomedical Applications
5. Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months
6. Synapse Biomedical Receives FDA Approval of NeuRx Diaphragm Pacing System (DPS)(TM) For Spinal Cord Injury Breathing Applications
7. Centocor and Janssen-Cilag Submit Applications Requesting Approval of Ustekinumab in the U.S. and Europe for Treatment of Moderate to Severe Plaque Psoriasis
8. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
9. Awardees for the 2009 Young Investigator Grant for Probiotics Research Announced
10. National Cancer Institute Research Identifies Unique Mechanism of Brostallicins Anti-Tumor Effectiveness
11. UPDATE: US Oncology Research Network Participates in Phase III Follow-up Study to BiPars Investigational Cancer Drug BSI-201
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... May 24, 2016 Celsion Corporation (NASDAQ: ... company, today provided an update on its ongoing ... trial combining GEN-1, the Company,s DNA-based immunotherapy, with ... newly-diagnosed patients with advanced ovarian cancer who will ... GEN-1 is an IL-12 DNA plasmid vector formulated ...
(Date:5/24/2016)... May 24, 2016 The ... world , s first dual therapy stent, ...   OrbusNeich, a global company specializing in ... portfolio to include products to treat peripheral artery disease. ... first entry devices for lower limb and arteriovenous (AV) ...
(Date:5/24/2016)... , May 24, 2016 ... ™ , la première endoprothèse à ... destinés à l,intervention portant sur les membres ... OrbusNeich, entreprise mondiale spécialisée dans ... changer la vie, a élargi son portefeuille ...
Breaking Medicine Technology:
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... ... readers, this installment is bolstered by inspiring human-interest stories, courtesy of awareness-driven celebrities ... within the industry, from leading advocates, associations and industry leaders such as Bioness. ...
(Date:5/27/2016)... ... May 27, 2016 , ... Each year Standard Process ... Outerbridge is this year’s Life University winner of a $2,500 scholarship ... Student Leadership Awards ceremony. , Outerbridge is approaching her last quarter at Life ...
(Date:5/26/2016)... ... May 26, 2016 , ... Cabot ... of defective respirators, according to court documents and SEC filings. A jury ... Becky Tyler v. American Optical Corporation, Case No. BC588866, Los Angeles County, California. ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... The ... Project offering a new model of care for living and healing, celebrated its ... values: Meaningful Life in a Real Home provided by Empowered Staff. , “This is ...
(Date:5/26/2016)... ... May 26, 2016 , ... Dr. James Maisel will present ... Island Chapter on June 4, 2016, 1:30-3:30 pm at the Farmingdale Public Library. ... Retina Group of New York , is a Board Certified ophthalmologist who completed ...
Breaking Medicine News(10 mins):